Skip to content
Open access

Functional status to predict acute care utilization among patients receiving systemic anticancer therapy in a QMENTUM diamond cancer center: A real-world cohort study.

Oct 2026 · JCO Oncology Practice · 0 citations

TL;DR

The findings support the incorporation of PS assessment into routine oncology practice to identify patients who may benefit from targeted supportive care strategies and closer monitoring, supporting proactive care delivery within high-quality oncology programs.

Abstract

92 Background: Acute care utilization (ACU), including emergency department (ED) visits, hospitalizations, and intensive care unit (ICU) admissions, is associated with increased healthcare costs, treatment interruptions, and worse patient outcomes. Identifying patients at increased risk for ACU may facilitate targeted supportive care interventions. Thus, we sought to identify clinical factors associated with ACU among patients receiving systemic anticancer therapy at a QMENTUM Diamond-accredited cancer center in Brazil. Methods: We conducted a retrospective cohort study of adult patients with solid tumors treated at a Brazilian cancer center between 2023 and 2025. The primary outcome was ACU, defined as the occurrence of at least one of the following within the follow-up period: ED visit within 30 days of treatment, hospitalization within 30 days, or ICU admission. Demographic and clinical variables included age, treatment intent, and Eastern Cooperative Oncology Group (ECOG) performance status (PS). Multivariable logistic regression was used to evaluate factors independently associated with ACU. Results: A total of 161 patients were included. The median age was 61 years (range, 25-92), with 42.9% were aged ≥65 years; 68.3% were female. The most common malignancies were breast (41.0%), gastrointestinal (23.6%), and gynecologic (6.2%) cancers. Most patients had advanced-stage disease (III-IV, 70.8%). Overall, 52 patients (32.3%) experienced ACU. ACU was more frequent among patients aged ≥65 years than among younger patients (43.5% vs. 23.9%, p=0.008), and among those receiving palliative versus curative-intent treatment (39.7% vs. 25.3%; p=0.06). A stepwise increase in ACU was observed with worsening PS, occurring in 14 of 76 patients (18.4%) with ECOG 0, 18 of 56 (32.1%) with ECOG 1, and 20 of 29 (69.0%) with ECOG ≥2 (p<0.001). In multivariable analysis adjusting for age and treatment intent, ECOG ≥2 remained independently associated with ACU (OR, 5.38; 95% CI, 2.07-13.97; p=0.001). Neither age ≥65 years (OR, 1.44; 95% CI, 0.67-3.09; p=0.35) nor palliative treatment intent (OR, 1.41; 95% CI, 0.68-2.93; p=0.35) was independently associated with ACU. Conclusions: In this real-world Brazilian cohort, ECOG PS was the strongest predictor of ACU. While older age and palliative treatment intent were associated with higher rates of acute care utilization in unadjusted analyses, only ECOG ≥2 remained independently associated with risk after adjustment. These findings support the incorporation of PS assessment into routine oncology practice to identify patients who may benefit from targeted supportive care strategies and closer monitoring, supporting proactive care delivery within high-quality oncology programs.

Read PDF

Similar papers

Review Open access Oct 2026

Outcomes of inpatient chemotherapy following multidisciplinary review in patients with solid tumors at an academic cancer center.

Nearly one-third of patients undergoing multidisciplinary review for inpatient chemotherapy died within 30 days of request, highlighting the medical complexity of this population of patients.

Lawanya Singh, Tristan Lee, D. Hershman et al. · 0 citations
Open access Oct 2026

Utility (or futility) of inpatient chemotherapy in patients with advanced solid organ cancers near end of life (FOCUS-EOL).

289 Background: Chemotherapy near the end of life carries limited clinical benefit. We evaluated outcomes of patients with solid organ malignancies who received inpatient cytotoxic chemotherapy at a tertiary cancer center. Methods: We performed a retrospective study of adults with solid organ malignancies who...

Adeel Arshad, P. Bhateja, Alyssa Antonini et al. · 0 citations
Open access Oct 2026

Clinical Spectrum, Indications, and Short-Term Outcomes of Invasive Mechanical Ventilation Among Cancer Patients in the Intensive Care Unit of a Tertiary Cancer Hospital in Nepal: A Retrospective Cohort Study

Background: Cancer patients increasingly require intensive care as oncologic therapy extends survival, and invasive mechanical ventilation (IMV) is one of the strongest independent predictors of mortality in this population. Geographic variation in outcomes has been described, with higher ICU mortality reported among A...

Yogesh Regmi, P. Thapa, B. Wagle et al. · 0 citations
Open access 2026

Charlson comorbidity index in predicting outcomes among patients in the medical intensive care unit at a tertiary care university hospital: A cross-sectional study

Background: In critical care, comorbidities significantly influence outcomes, but they are often underutilized in real-time decision-making. The Charlson Comorbidity Index (CCI), a widely validated tool for quantifying comorbid burden, offers a practical way to assess prognosis in intensive care unit (ICU) patient...

Nishant Rathod, Sunil Kumar, S. Acharya et al. · 0 citations
Review Open access Oct 2026

Impact of Remote Symptom Monitoring on Acute Care Utilization in Patients with Advanced Cancer Undergoing Phase I Therapies: Secondary Analysis of a Randomized Clinical Trial

Purpose: Patients undergoing phase I cancer therapies experience high symptom burden and complications that may lead to emergency department (ED) visits and hospitalizations. It is unclear whether remote symptom monitoring (RSM) reduces acute care utilization. We conducted a secondary analysis of a randomized clinical...

J. Stover, Matthew Meranda, I. Subbiah et al. · 0 citations
Open access Oct 2026

Systemic anticancer therapy near the end of life and acute health care utilization: A target trial emulation study using SEER–Medicare.

612 Background: Use of Systemic anticancer therapy (SACT) at end-of-life (EOL) has been associated with higher costs, increased hospitalizations (HL), emergency department (ED), and intensive care unit (ICU) utilization and lower hospice (HP) use all of which may adversely affect quality of life. Prior studies...

Maureen E. Canavan, Lee Cheng, Jian-Gong Niu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.